Fluorophore

Columbia Biosciences and Kemp Proteins Enter Strategic Partnership for Fluorophore Conjugation Solutions

Retrieved on: 
Tuesday, April 2, 2024
Partnership, Research, Strategic partnership, Protein, Quality management system, Therapy, Fluorophore

FREDERICK, Md., April 2, 2024 /PRNewswire-PRWeb/ -- Columbia Biosciences Corp, a leading provider of fluorescent dyes and custom conjugation services, today announced that the company has entered a Strategic Partnership with Kemp Proteins LLC of Frederick, Maryland. This collaboration combines Kemp Proteins' antibody development and protein manufacturing services with Columbia Biosciences' expertise in protein and antibody conjugation. The combination of Kemp's ability to develop and manufacture gram quantities of proteins and monoclonal antibodies for its clients, together with Columbia's experience in custom conjugation and critical reagent development, will provide a streamlined opportunity to generate client-directed, custom-tailored ready-to-use molecular tools manufactured under ISO13485:2016 compliant Quality Management Systems.

Key Points: 
  • FREDERICK, Md., April 2, 2024 /PRNewswire-PRWeb/ -- Columbia Biosciences Corp, a leading provider of fluorescent dyes and custom conjugation services, today announced that the company has entered a Strategic Partnership with Kemp Proteins LLC of Frederick, Maryland.
  • This collaboration combines Kemp Proteins' antibody development and protein manufacturing services with Columbia Biosciences' expertise in protein and antibody conjugation.
  • Under the Partnership, Kemp Proteins will utilize its proven monoclonal antibody development and gene-to-protein capabilities to produce, purify and QC the antibodies/proteins for supply to Columbia Biosciences for fluorescent labeling.
  • John Morseman, CEO of Columbia Biosciences, echoed Keefe's sentiments: "Columbia Biosciences and Kemp Proteins can leverage their respective strengths to provide turnkey solutions for biopharma and life science clients, accelerating research and development efforts in diagnostics and therapeutics."

Live Cell Imaging Market to Reach $5.2 Billion, Globally, by 2032 at 8.2% CAGR: Allied Market Research

Retrieved on: 
Tuesday, December 12, 2023
B cell, HCS, Cell biology, Observation, Research, Fluorophore, Investment, Biotechnology, Growth, Regenerative medicine, Drug discovery, Cell division, Drug development, Fine chemical, Mobile phone

PORTLAND, Ore., Dec. 12, 2023 /PRNewswire/ -- Allied Market Research published a report, titled, "Live Cell Imaging Market by Product Type (Instruments, Accessories and Consumables and Software), Application (Cell Biology, Stem Cells, Developmental Biology, and Drug Discovery), Technology (Time-lapse Microscopy, Fluorescence Resonance Energy Transfer (FRET), Fluorescence Recovery After Photobleaching (FRAP), High-Content Screening (HCS), and Other Technologies) and End User (Pharmaceutical and Biotechnological Companies, Academic and Research Institutes, Contract Research Organizations, and Others): Global Opportunity Analysis and Industry Forecast, 2023–2032". According to the report, the global live cell imaging industry generated $2.3 billion in 2022 and is anticipated to generate $5.2 billion by 2032, witnessing a CAGR of 8.2% from 2023 to 2032.

Key Points: 
  • Moreover, it hampers investments in live cell imaging technology development, slowing down innovation and the introduction of advanced imaging systems.
  • Diseases and health concerns persist regardless of economic conditions, potentially leading to sustained demand for live cell imaging technologies in critical areas such as disease research, diagnostics, and drug development.
  • This is attributed to increase in funding allocations research studies, promoting adoption of advanced live cell imaging technologies for varied biological studies.
  • In addition, robust funding environment, coupled with supportive government initiatives, has propelled the adoption of innovative imaging techniques such as live cell imaging in academic and research institutions.

Live Cell Imaging Market to Reach $5.2 Billion, Globally, by 2032 at 8.2% CAGR: Allied Market Research

Retrieved on: 
Tuesday, December 12, 2023
B cell, HCS, Cell biology, Observation, Research, Fluorophore, Investment, Biotechnology, Growth, Regenerative medicine, Drug discovery, Cell division, Drug development, Fine chemical, Mobile phone

PORTLAND, Ore., Dec. 12, 2023 /PRNewswire/ -- Allied Market Research published a report, titled, "Live Cell Imaging Market by Product Type (Instruments, Accessories and Consumables and Software), Application (Cell Biology, Stem Cells, Developmental Biology, and Drug Discovery), Technology (Time-lapse Microscopy, Fluorescence Resonance Energy Transfer (FRET), Fluorescence Recovery After Photobleaching (FRAP), High-Content Screening (HCS), and Other Technologies) and End User (Pharmaceutical and Biotechnological Companies, Academic and Research Institutes, Contract Research Organizations, and Others): Global Opportunity Analysis and Industry Forecast, 2023–2032". According to the report, the global live cell imaging industry generated $2.3 billion in 2022 and is anticipated to generate $5.2 billion by 2032, witnessing a CAGR of 8.2% from 2023 to 2032.

Key Points: 
  • Moreover, it hampers investments in live cell imaging technology development, slowing down innovation and the introduction of advanced imaging systems.
  • Diseases and health concerns persist regardless of economic conditions, potentially leading to sustained demand for live cell imaging technologies in critical areas such as disease research, diagnostics, and drug development.
  • This is attributed to increase in funding allocations research studies, promoting adoption of advanced live cell imaging technologies for varied biological studies.
  • In addition, robust funding environment, coupled with supportive government initiatives, has propelled the adoption of innovative imaging techniques such as live cell imaging in academic and research institutions.

Sony Announces Launch of FP7000 Spectral Cell Sorter Supporting High-Parameter Sorting with More Than 44 Colors(*1)

Retrieved on: 
Monday, October 9, 2023
Pressure, Fluorophore, Sony, Automation, PCR, Cell, Power source, Microfluidics, Calibration, 6-way, Flow cytometry, Subjectivity, Electronics, Laser, 4-way, Cell biology, Research, Microscope, Television, Fine chemical

TOKYO, Oct. 9, 2023 /PRNewswire/ -- Sony Corporation ("Sony") today announced the launch of FP7000 spectral cell sorter that supports high-speed, high-parameter sorting with more than 44 colors with simple workflows, leveraging its patented spectral technology-based optics, advanced electronics and fluidics.

Key Points: 
  • -Meeting the evolving needs in immunology, cell biology and oncology-
    TOKYO, Oct. 9, 2023 /PRNewswire/ -- Sony Corporation ("Sony") today announced the launch of FP7000 spectral cell sorter that supports high-speed, high-parameter sorting with more than 44 colors with simple workflows, leveraging its patented spectral technology-based optics, advanced electronics and fluidics.
  • The new high-parameter spectral cell sorter is configurable with up to 6 lasers and 182 detectors enabling the detection and sorting of cell populations of interest, using complex panels comprised of more than 44 colors.
  • FP7000 spectral cell sorter is scheduled to be available in autumn 2024.
  • Optical capability is matched to Sony's ID7000™ Spectral Cell Analyzer thus enabling multicolor assay portability from the cell analyzer to the cell sorter.

Study Helps Explain How COVID-19 Heightens Risk of Heart Attack and Stroke

Retrieved on: 
Thursday, September 28, 2023
Infection, Heart, Plaque, Fluorophore, Coronavirus, Macrophage, Icahn School of Medicine at Mount Sinai, American Heart Association, Palpitations, SARS-CoV-2, Stroke, COVID-19, NYU, Splenic infarction, New York University Grossman School of Medicine, Woman, Intelligence, Chest pain, Brain, Artery, Research, COVID, Department of Medicine – University of Pamplona, Inflammation, History, Doctor of Philosophy, Atherosclerosis, Cell, Bachelor of Science, MS, Bangladesh Technical Education Board, NYU Langone Health, Blood, Mount Sinai, Rupture, Patient, Pathology, Swelling, Immune system, Cytokine, MPH, Behavior, Fatigue, Disease, Vaccine, Pharmaceutical industry, Medical imaging, MD, Medicine

Experts have long observed that the COVID-19 coronavirus increases the likelihood of having a heart attack or stroke for up to a year after infection, particularly for those who already have underlying heart conditions.

Key Points: 
  • Experts have long observed that the COVID-19 coronavirus increases the likelihood of having a heart attack or stroke for up to a year after infection, particularly for those who already have underlying heart conditions.
  • Notably, the researchers say, two of the identified cytokines, interleukin-1 beta and interluekin-6, have already been linked to heart attacks.
  • "These results shed light onto a possible connection between preexisting heart issues and long COVID symptoms," said study senior author and cardiologist Chiara Giannarelli, MD, PhD.
  • Further funding was provided by the American Heart Association grant 20SFRN35210252 and a Chan Zuckerberg Initiative grant.

Global Immunofluorescence Assay Market to 2030: Increasing Prevalence of Chronic and Infectious Diseases Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, June 6, 2023
Research, Science, HIV/AIDS, Fluorophore, Prevalence, HIV, COVID-19, Microscopy, Infection, Chron, Crohn's disease, Antibody, CDC, Alzheimer's disease, Protein, Point-of-care testing, Growth, WHO, Arecaceae, European Commission, Disease, Microscope, Vaccine, Pharmaceutical industry, Immunofluorescence

Increasing prevalence of chronic and infectious diseases, significant applications of immunofluorescence assay (IFA) in several areas and technological advancements in techniques and associated instruments are key factors driving the market growth.

Key Points: 
  • Increasing prevalence of chronic and infectious diseases, significant applications of immunofluorescence assay (IFA) in several areas and technological advancements in techniques and associated instruments are key factors driving the market growth.
  • The immunofluorescence assay market is anticipated to witness rapid growth, owing to the technological advances and launch of novel instruments.
  • For instance, in November 2020, CTK Biotech, Inc. introduced RaFIA immunofluorescence immunoassay system to meet the rising demand for quantitative rapid tests.
  • Hence, the growing awareness and increasing demand for the detection and cure of several chronic and infectious diseases are some of the driving factors for the market growth.

Pusan National University Develops Novel Biosensor to Detect DNA Damage in Real Time

Retrieved on: 
Tuesday, March 14, 2023
Plasmid, Associate, FRET, H2AX, Environment, Pusan National University, Energy, Wireless power transfer, Cell, Fluorophore, DNA, DSB, Orientation, DNA repair, Drug discovery, Protein, Vaccine, Microscope

BUSAN, South Korea, March 14, 2023 /PRNewswire/ -- Scientists from Korea have developed a new biosensor that uses fluorescence resonance energy transfer (FRET) to detect DNA double-strand breaks in living specimens in real time. This biosensor has the potential to revolutionize cancer treatment by helping doctors understand how cells respond to treatment and facilitating the discovery of new DNA repair drugs. It can also aid the development of new treatments for DNA damage-related diseases by revealing how our bodies repair damaged DNA.

Key Points: 
  • It can also aid the development of new treatments for DNA damage-related diseases by revealing how our bodies repair damaged DNA.
  • Double-strand breaks (DSBs) are a type of DNA damage where both strands of DNA break at the same location.
  • Currently, DSBs are detected by immunostaining techniques, which identify markers that accompany DNA damage, such as the protein γH2AX.
  • However, these methods are tedious, and cannot be used to detect DSBs in real time in living specimens.

Ningbo of China: Anchoring the Goal of "Emission Peak and Carbon Neutrality"

Retrieved on: 
Friday, March 10, 2023
Carbon, Coal, Attention, Chemical industry, Brain, Social Security, Government, Human resources, Work, Fluorophore, Social, NPC, City, CPPCC, Renewable energy

Blue carbon, also known as blue carbon exchange reserves or marine carbon exchange reserves, is a master of capturing carbon dioxide as well as a treasure trove of storing carbon dioxide, and has a carbon storage cycle reaching several thousand years.

Key Points: 
  • Blue carbon, also known as blue carbon exchange reserves or marine carbon exchange reserves, is a master of capturing carbon dioxide as well as a treasure trove of storing carbon dioxide, and has a carbon storage cycle reaching several thousand years.
  • In the context of accelerating the construction of emission peak and carbon neutrality, global blue carbon trading is becoming more and more active.
  • It was Ningbo's first exploration to shape the national blue carbon trading market, and it was also Ningbo's first beneficial exploration of the practice of emission peak and carbon neutrality.
  • In 2023, Ningbo will co-ordinate the "four dimensions" of economic growth, energy security, carbon emissions, and residents' lives, promote the carbon reduction, pollution abatement, expansion of environmental protection and growth accordantly, actively and steadily encourage the emission peak and carbon neutrality, and implement the "Top Ten Actions for Emission Peak".

Ningbo, China: Anchoring the Goal of "Emission Peak and Carbon Neutrality"; Exploring the Construction of a Coastal Model City based on the "Emission Peak and Carbon Neutrality"

Retrieved on: 
Friday, March 10, 2023
Carbon, Coal, Attention, Chemical industry, Brain, Social Security, Government, Human resources, Work, Fluorophore, Social, NPC, City, CPPCC, Natural gas, Renewable energy

NINGBO, China, March 10, 2023 /PRNewswire/ -- "As an eastern coastal city, Ningbo is rich in 'carbon exchange reserve' resources.

Key Points: 
  • NINGBO, China, March 10, 2023 /PRNewswire/ -- "As an eastern coastal city, Ningbo is rich in 'carbon exchange reserve' resources.
  • This year's Report on the Work of the Government has mentioned: Continuing the transition to green development.
  • In the context of accelerating the construction of emission peak and carbon neutrality, global blue carbon trading is becoming more and more active.
  • Through the construction of application scenarios, the carbon capabilities and carbon assets of enterprises were comprehensively characterized, providing accurate services for inclusive small and micro loans.

Flow Cytometry Global Market Report 2022: High R&D Investments In Biotechnology, Clinical, And Life Science Research Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 3, 2023
Biotechnology, Infectious Diseases, Other Health, Biometrics, Health, Cancer, Fluorophore, Ventilation, Drug development, Flow cytometry, COVID-19, Microfluidics, Asia-Africa Growth Corridor, USD, ICU, Haematopoietic system, Life Sciences Research Office, Growth, Patient, Infection, Organ transplantation, Investment, POC, Cell, Industrial, Bead, Prevalence, WHO, Fine chemical, Pharmaceutical industry, Biotechnology, Software

The global flow cytometry market size is expected to reach USD 9.28 billion by 2030, registering a CAGR of 7.07% over the forecast period.

Key Points: 
  • The global flow cytometry market size is expected to reach USD 9.28 billion by 2030, registering a CAGR of 7.07% over the forecast period.
  • In addition, increasing R&D investments in biopharmaceutical, life science, and biotechnology research activities have led to high demand for flow cytometry instruments.
  • In recent years, a key focus has been on the development of portable microfluidic flow cytometry devices for PoC testing.
  • High R&D Investments In Biotechnology, Clinical, And Life Science Research